Doses - PHOSPHATE, PARENTERAL, POTASSIUM PHOSPHATE, SODIUM PHOSPHATE

Both sodium and potassium phosphate injections must be diluted before intravenous administration.

Dogs & Cats:

For hypophosphatemia:
a) For significant hypophosphatemia (<1.5 mg/dl) in patients unable to receive oralsupplementation: 0.06 - 0.18 mM/kg IV given over 6 hours (0.01 - 0.03 mM/kg/hr).
Recheck serum phosphorous before continuing. Usually may stop therapy when serumphosphorous level reaches 2 mg/dl. (Hardy and Adams 1989)
b) Cats: For severe hypophosphatemia in diabetic ketoacidosis: Using potassium phosphate give 0.01 - 0.03 mM/kg/hr for 6 hours IV. Recheck serum phosphorous beforecontinuing. In order to provide enough potassium without inducing hyperphosphatemia, supply 50-75% of patient's potassium using potassium chloride and the remainder aspotassium phosphate. (Peterson and Randolph 1989)
Monitoring Parameters -

1) Serum inorganic phosphate (phosphorous)

2) Other electrolytes, including calcium
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: There are no parenteral phosphate-only products approved forveterinary medicine. There are, however, several proprietary phosphate-containing products availablethat may also include calcium, magnesium, potassium and/or dextrose; refer to the individualproduct's labeling for specific dosage information. Trade names for these products include:
Magnadex®¯Osborn, Norcalciphos®¯SKB, Cal-Dextro® Special, & #2, ¯Fort Dodge, and CMPK®, & Cal-Phos® #2¯(TechAmerica). They are legend (Rx) drugs.

Human-Approved Products:

Potassium Phosphate Injection; each ml provides 3 mM of phosphate (99.1 mg/dl of phosphorous) and 4.4 mEq of potassium per ml in 5, 10, 15, 30, & 50 ml vials
Generic; (Rx)
Sodium Phosphate Injection; each ml provides 3 mM of phosphate (93 mg/dl of phosphorous)and 4 mEq of sodium per ml in 10, 15, 30, and 50 ml vials; Generic; (Rx)